Jean-Philippe Tripet, CFA, is a Managing Partner and founder of Aravis. Aravis now employs 12 investment professionals and is a leading Swiss Private equity and Venture house. During his career Jean Philippe has performed and supervised over 100 investments in private companies in the USA, Europe and Asia, many as lead investor. He has developed experience as international bank executive, private equity investor, portfolio manager and as financial analyst since 1988. He was in particular active in seeding and founding of some of the most successful Swiss biotech companies such as Glycart, Cytos, Modex-Isotis, Esbatech, Evolva, Symetis, Telormedix and Novimmune.
Jean-Philippe sits on the board of directors or committees of companies in Europe (Telormedix, Symetis) and Asia (S Bio, Merlion). He was a director of Evolva (SWX:EVE), Synosia (now Biotie BTH1V:FH) and Omeros (NASDAQ: OMER). Jean-Philippe is a member of the Executive Commitee of the Swiss Private Equity and Venture Capital Association (SECA) and the current Chairman of the Venture Chapter. He is the initiator and leader of the project Swissfund focusing on creating new sources of funding for startups.
Prior to founding Aravis he was a Senior Executive Vice-President and Head of Sector asset management and research at Lombard Odier & Cie, Geneva and a member of the Group Executive Committee of the bank. Before that he was vice- President, Equity Research at UBS in Zurich and London.
He has a degree in business administration from the University of Geneva, did graduate studies in finance in San Diego, California and is a Chartered Financial Analyst.
Since 1998 he sits as coach and jury member of the ETH-Mc Kinsey Business plan competition, as well as in the jury of Venture Kick. He is also a former Director of the Fondation Fournier Majoie pour l’innovation in Bruxelles.
